Clinical and molecular characteristics of a series of 192 patients with AML
| Characteristic . | No. (%) . |
|---|---|
| Sex | |
| Male | 99 (53) |
| Female | 88 (47) |
| No data | 5 |
| Age | |
| Less than 60 years | 92 (50.3) |
| More than 60 years | 91 (49.7) |
| No data | 9 |
| Complete remission | |
| No | 47 (36.7) |
| Yes | 81 (63.3) |
| No data | 64 |
| Diagnosis | |
| AML-M0 | 21 (10.9) |
| AML-M1 | 35 (18.2) |
| AML-M2 | 38 (19.8) |
| AML-M3 | 7 (3.6) |
| AML-M4 | 33 (17.2) |
| AML-M5 | 36 (18.8) |
| AML-M6 | 12 (6.3) |
| AML-NOS | 10 (5.2) |
| Secondary AML | |
| No | 130 (83.3) |
| Yes | 26 (16.7) |
| No data | 36 |
| Cytogenetic group | |
| Good | 29 (15) |
| Intermediate | 92 (48) |
| Poor | 71 (37) |
| SETBP1 overexpression | |
| No | 139 (72.4) |
| Yes | 53 (27.6) |
| WT1 overexpression | |
| No | 22 (16) |
| Yes | 115 (84) |
| No data | 55 |
| EVI1 overexpression | |
| No | 132 (76.7) |
| Yes | 40 (23.3) |
| No data | 20 |
| NPM1 mutated | |
| No | 18 (37.5) |
| Yes | 30 (62.5) |
| No data | 144 |
| FLT3-ITD | |
| No | 99 (79.2) |
| Yes | 26 (20.8) |
| No data | 67 |
| Characteristic . | No. (%) . |
|---|---|
| Sex | |
| Male | 99 (53) |
| Female | 88 (47) |
| No data | 5 |
| Age | |
| Less than 60 years | 92 (50.3) |
| More than 60 years | 91 (49.7) |
| No data | 9 |
| Complete remission | |
| No | 47 (36.7) |
| Yes | 81 (63.3) |
| No data | 64 |
| Diagnosis | |
| AML-M0 | 21 (10.9) |
| AML-M1 | 35 (18.2) |
| AML-M2 | 38 (19.8) |
| AML-M3 | 7 (3.6) |
| AML-M4 | 33 (17.2) |
| AML-M5 | 36 (18.8) |
| AML-M6 | 12 (6.3) |
| AML-NOS | 10 (5.2) |
| Secondary AML | |
| No | 130 (83.3) |
| Yes | 26 (16.7) |
| No data | 36 |
| Cytogenetic group | |
| Good | 29 (15) |
| Intermediate | 92 (48) |
| Poor | 71 (37) |
| SETBP1 overexpression | |
| No | 139 (72.4) |
| Yes | 53 (27.6) |
| WT1 overexpression | |
| No | 22 (16) |
| Yes | 115 (84) |
| No data | 55 |
| EVI1 overexpression | |
| No | 132 (76.7) |
| Yes | 40 (23.3) |
| No data | 20 |
| NPM1 mutated | |
| No | 18 (37.5) |
| Yes | 30 (62.5) |
| No data | 144 |
| FLT3-ITD | |
| No | 99 (79.2) |
| Yes | 26 (20.8) |
| No data | 67 |
AML indicates acute myeloid leukemia.